Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced its 2025 first extraordinary general meeting to discuss and approve several key resolutions. These include the adoption of the 2025 A Share Option Scheme and the 2025 H Share RSU Scheme, as well as the renewal of financial and mutual supply agreements with Fosun Finance and Sinopharm. The resolutions aim to enhance the company’s financial management and operational efficiency, potentially impacting its strategic positioning and stakeholder relationships.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai…
